Afexa Life Sciences Articles
Battle for Afexa escalates as suitors Valeant and Paladin up offers; Dr Reddy’s and JBCPL scrap Russian deal
27 September 2011
Showing 1-2 of 2 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
